Management of extreme thrombocytosis in myeloproliferative neoplasms

an international physician survey

Maya Koren-Michowitz, Noa Lavi, Martin H. Ellis, Alessandro M. Vannucchi, Ruben Mesa, Claire N. Harrison

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Extreme thrombocytosis (ExT) has been associated with an increased bleeding risk in myeloproliferative neoplasm (MPN) patients and is included in the high risk category in treatment guidelines. Treatment of patients with ExT has not been studied in prospective trials. To study physicians’ approaches to ExT, we distributed a web based questionnaire with clinical case scenarios to 202 members of MPN working groups. Cases included low thrombotic risk essential thrombocythemia (ET) with either JAK2V617F or CALR mutation, polycythemia vera with ExT either with or without leukocytosis, an ET patient needing urgent orthopedic surgery, and a poorly controlled ET patient with acute cerebral venous sinus thrombosis. Responses were received from 90 physicians (45 %) and were variable in most case scenarios. Country of practice had the most significant influence on physician response. The USA and Israel physicians responded similarly in most cases and differently to the Europe physicians. Treatment of asymptomatic JAK2V617F positive ET and target platelet count on cytoreduction were significantly influenced by physician years of experience. Responses were not influenced by the volume of MPN practice or by whether MPN was considered a major interest by the physician. Our results show a lack of consensus on how to manage MPN patients with ExT. Randomized controlled trials properly designed to address these questions are needed.

Original languageEnglish (US)
Pages (from-to)87-92
Number of pages6
JournalAnnals of Hematology
Volume96
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Thrombocytosis
Essential Thrombocythemia
Physicians
Neoplasms
Intracranial Sinus Thrombosis
Polycythemia Vera
Leukocytosis
Israel
Surveys and Questionnaires
Platelet Count
Venous Thrombosis
Orthopedics
Therapeutics
Randomized Controlled Trials
Guidelines
Hemorrhage
Mutation

Keywords

  • Acquired von Willebrand disease
  • Bleeding
  • Myeloproliferative neoplasm
  • Thrombocytosis

ASJC Scopus subject areas

  • Hematology

Cite this

Koren-Michowitz, M., Lavi, N., Ellis, M. H., Vannucchi, A. M., Mesa, R., & Harrison, C. N. (2017). Management of extreme thrombocytosis in myeloproliferative neoplasms: an international physician survey. Annals of Hematology, 96(1), 87-92. https://doi.org/10.1007/s00277-016-2826-4

Management of extreme thrombocytosis in myeloproliferative neoplasms : an international physician survey. / Koren-Michowitz, Maya; Lavi, Noa; Ellis, Martin H.; Vannucchi, Alessandro M.; Mesa, Ruben; Harrison, Claire N.

In: Annals of Hematology, Vol. 96, No. 1, 01.01.2017, p. 87-92.

Research output: Contribution to journalArticle

Koren-Michowitz, M, Lavi, N, Ellis, MH, Vannucchi, AM, Mesa, R & Harrison, CN 2017, 'Management of extreme thrombocytosis in myeloproliferative neoplasms: an international physician survey', Annals of Hematology, vol. 96, no. 1, pp. 87-92. https://doi.org/10.1007/s00277-016-2826-4
Koren-Michowitz, Maya ; Lavi, Noa ; Ellis, Martin H. ; Vannucchi, Alessandro M. ; Mesa, Ruben ; Harrison, Claire N. / Management of extreme thrombocytosis in myeloproliferative neoplasms : an international physician survey. In: Annals of Hematology. 2017 ; Vol. 96, No. 1. pp. 87-92.
@article{7c640b85ec8f4856a1516c7bf2cf4bc9,
title = "Management of extreme thrombocytosis in myeloproliferative neoplasms: an international physician survey",
abstract = "Extreme thrombocytosis (ExT) has been associated with an increased bleeding risk in myeloproliferative neoplasm (MPN) patients and is included in the high risk category in treatment guidelines. Treatment of patients with ExT has not been studied in prospective trials. To study physicians’ approaches to ExT, we distributed a web based questionnaire with clinical case scenarios to 202 members of MPN working groups. Cases included low thrombotic risk essential thrombocythemia (ET) with either JAK2V617F or CALR mutation, polycythemia vera with ExT either with or without leukocytosis, an ET patient needing urgent orthopedic surgery, and a poorly controlled ET patient with acute cerebral venous sinus thrombosis. Responses were received from 90 physicians (45 {\%}) and were variable in most case scenarios. Country of practice had the most significant influence on physician response. The USA and Israel physicians responded similarly in most cases and differently to the Europe physicians. Treatment of asymptomatic JAK2V617F positive ET and target platelet count on cytoreduction were significantly influenced by physician years of experience. Responses were not influenced by the volume of MPN practice or by whether MPN was considered a major interest by the physician. Our results show a lack of consensus on how to manage MPN patients with ExT. Randomized controlled trials properly designed to address these questions are needed.",
keywords = "Acquired von Willebrand disease, Bleeding, Myeloproliferative neoplasm, Thrombocytosis",
author = "Maya Koren-Michowitz and Noa Lavi and Ellis, {Martin H.} and Vannucchi, {Alessandro M.} and Ruben Mesa and Harrison, {Claire N.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1007/s00277-016-2826-4",
language = "English (US)",
volume = "96",
pages = "87--92",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Management of extreme thrombocytosis in myeloproliferative neoplasms

T2 - an international physician survey

AU - Koren-Michowitz, Maya

AU - Lavi, Noa

AU - Ellis, Martin H.

AU - Vannucchi, Alessandro M.

AU - Mesa, Ruben

AU - Harrison, Claire N.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Extreme thrombocytosis (ExT) has been associated with an increased bleeding risk in myeloproliferative neoplasm (MPN) patients and is included in the high risk category in treatment guidelines. Treatment of patients with ExT has not been studied in prospective trials. To study physicians’ approaches to ExT, we distributed a web based questionnaire with clinical case scenarios to 202 members of MPN working groups. Cases included low thrombotic risk essential thrombocythemia (ET) with either JAK2V617F or CALR mutation, polycythemia vera with ExT either with or without leukocytosis, an ET patient needing urgent orthopedic surgery, and a poorly controlled ET patient with acute cerebral venous sinus thrombosis. Responses were received from 90 physicians (45 %) and were variable in most case scenarios. Country of practice had the most significant influence on physician response. The USA and Israel physicians responded similarly in most cases and differently to the Europe physicians. Treatment of asymptomatic JAK2V617F positive ET and target platelet count on cytoreduction were significantly influenced by physician years of experience. Responses were not influenced by the volume of MPN practice or by whether MPN was considered a major interest by the physician. Our results show a lack of consensus on how to manage MPN patients with ExT. Randomized controlled trials properly designed to address these questions are needed.

AB - Extreme thrombocytosis (ExT) has been associated with an increased bleeding risk in myeloproliferative neoplasm (MPN) patients and is included in the high risk category in treatment guidelines. Treatment of patients with ExT has not been studied in prospective trials. To study physicians’ approaches to ExT, we distributed a web based questionnaire with clinical case scenarios to 202 members of MPN working groups. Cases included low thrombotic risk essential thrombocythemia (ET) with either JAK2V617F or CALR mutation, polycythemia vera with ExT either with or without leukocytosis, an ET patient needing urgent orthopedic surgery, and a poorly controlled ET patient with acute cerebral venous sinus thrombosis. Responses were received from 90 physicians (45 %) and were variable in most case scenarios. Country of practice had the most significant influence on physician response. The USA and Israel physicians responded similarly in most cases and differently to the Europe physicians. Treatment of asymptomatic JAK2V617F positive ET and target platelet count on cytoreduction were significantly influenced by physician years of experience. Responses were not influenced by the volume of MPN practice or by whether MPN was considered a major interest by the physician. Our results show a lack of consensus on how to manage MPN patients with ExT. Randomized controlled trials properly designed to address these questions are needed.

KW - Acquired von Willebrand disease

KW - Bleeding

KW - Myeloproliferative neoplasm

KW - Thrombocytosis

UR - http://www.scopus.com/inward/record.url?scp=84991113169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991113169&partnerID=8YFLogxK

U2 - 10.1007/s00277-016-2826-4

DO - 10.1007/s00277-016-2826-4

M3 - Article

VL - 96

SP - 87

EP - 92

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 1

ER -